StockMarketWire.com - Tiziana Life Sciences said it had completed patient enrollment for a clinical trial of a treatment for hepatocellular carcinoma.

The Phase 2a repeated-dose, six-month duration study would evaluate safety, tolerability and anti-tumor activity of Milciclib in Sorafenib-refractory or -intolerant patients with unresectable or metastatic HCC.

Topline data from the multi-center trial, being conducted in Italy, Greece and Israel, would be available in the second quarter of 2019.


At 8:08am: [LON:TILS] Tiziana Life Sciences Plc share price was +1.5p at 65p



Story provided by StockMarketWire.com